Improvements seen in adolescent psoriasis with ustekinumab
The CADMUS trial showed improvements in moderate to severe psoriasis in adolescent patients 12 years or older treated with ustekinumab, a study showed.
Treatment of psoriasis in pediatric patients is complicated by the limited number of approved treatments, despite approximately one-third of...
Source: Skin and Allergy News - Category: Dermatology Source Type: news
More News: Allergy | Allergy & Immunology | Dermatology | Pediatrics | Psoriasis | Skin | Stelara | Study